Want to see ORKA full AI Analyst Report?

Oruka Therapeutics (ORKA) Price & Analysis

836 Followers

ORKA Stock Chart & Stats

$92.16

-$1.96(-2.13%)

At close: Jul 27 4:00 PM EDT

$92.16

-$1.96(-2.13%)

Day’s Range― - ―

52-Week Range$12.84 - $97.78

Previous Close$89.8

Volume744.14K

Average Volume (3M)1.51M

Market Cap

$5.56B

Enterprise Value$2.61B

Total Cash (Recent Filing)$388.83M

Total Debt (Recent Filing)$1.81M

Price to Earnings (P/E)―

Beta1.08

Next Earnings

Aug 17, 2026

EPS Estimate

-0.51

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-2.39

Shares Outstanding60,312,100

10 Day Avg. Volume970,993

30 Day Avg. Volume1,505,454

Financial Highlights & Ratios

PEG Ratio0.24

Price to Book (P/B)2.93

Price to Sales (P/S)0.00

P/FCF Ratio-15.64

Enterprise Value/Market Cap0.47

Enterprise Value/RevenueN/A

Enterprise Value/Gross Profit-36.72K

Enterprise Value/Ebitda-22.44

Forecast

1Y Price Target

$147.63

Price Target Upside60.18% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering10

EPS Forecast (FY)-2.11

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Low Leverage And Large Equity BaseExtremely low debt and a large equity base materially reduce refinancing and interest-rate risk for a pre-revenue biotech. This structural financial flexibility supports multi-year clinical programs, strategic partnering, and optionality without immediate reliance on dilutive financing.

Differentiated Phase 2a Efficacy And TolerabilityHigh skin‑clearance rates and a placebo‑comparable safety profile provide durable clinical differentiation versus IL‑23 class peers. Long-acting pharmacokinetics that enable annual dosing could create a sustainable competitive advantage through convenience, adherence, and commercial premium.

Completed Equity Offering Strengthens Cash RunwayA sizable post-offering cash position materially extends runway to fund ongoing Phase 2b enrollment and additional trials. This reduces near-term financing pressure, enabling disciplined development decisions and more favorable timing on partnering or commercial planning.

Bears Say

Pre-revenue With Widening Net LossesBeing pre-revenue with growing operating losses means long lead times to commercialization and profitability. Persistent negative returns on equity and expanding deficits increase dependency on external capital and raise execution risk across clinical and commercial milestones.

Heavy And Rising Cash BurnOperating and free cash outflows have increased materially year-over-year, signaling sustained funding needs. Even with current liquidity, the structural burn rate pressures long-term funding strategy and could force dilutive raises or constrain R&D depth if trial timelines lengthen.

IL-23 License Dosing Restrictions Limit Strategic ScopeContractual dosing limits constrain development and partnering options in inflammatory bowel disease for years, narrowing near-term indication expansion. These structural restrictions can delay market entry, reduce addressable market access, and complicate strategic collaborations or transactions.

Oruka Therapeutics News

3 Healthcare Stocks with Strong Upside to Consider in July 2026, According to Analysts

Healthcare remains one of the market’s most steady sectors this year, backed by biotech innovation and medical device...

25d ago

BSX

INSM

Oruka Therapeutics falls -8.1%

Oruka Therapeutics (ORKA) is down -8.1%, or -$7.60 to $85.69. Published first on TheFly – the ultimate source...

26d ago

ORKA

Oruka Therapeutics price target raised to $130 from $100 at UBS

UBS raised the firm’s price target on Oruka Therapeutics (ORKA) to $130 from $100 and keeps a Buy...

27d ago

ORKA

BTIG says others may be interested in Apogee Therapeutics

BTIG analyst Julian Harrison says AbbVie (ABBV) can leverage its existing dermatology channels and compete in atopic dermatitis...

1M ago

JNJ

NVS

Oruka Therapeutics Shareholders Back Governance and Executive Pay

Oruka Therapeutics ( ($ORKA) ) has issued an update. At its June 2, 2026 annual meeting, Oruka Therapeutics...

2M ago

ORKA

Kapoor Reiterates Buy on Oruka Therapeutics as Pipeline Advances; Keeps $120 Price Target Unchanged

H.C. Wainwright analyst Mitchell Kapoor has reiterated their bullish stance on ORKA stock, giving a Buy rating yesterday....

2M ago

ORKA

Oruka Therapeutics Expands IL-23 License, Adds Dosing Limits

An update from Oruka Therapeutics ( ($ORKA) ) is now available. On May 29, 2026, Oruka Therapeutics, Inc....

2M ago

ORKA

Oruka: Strong ORKA-001 Clinical Profile and Pipeline Momentum Support Reiterated Buy Rating and Unchanged $120 Price Target

Analyst Mitchell Kapoor of H.C. Wainwright reiterated a Buy rating on Oruka Therapeutics, retaining the price target of...

2M ago

ORKA

Julian Harrison Reiterates Buy on Oruka Therapeutics, Maintains $151 Price Target on Strong Clinical Profile and Cash Position

Analyst Julian Harrison of BTIG maintained a Buy rating on Oruka Therapeutics, retaining the price target of $151.00....

3M ago

ORKA

Oruka Initiated With Buy on Best-in-Class ORKA-001 Psoriasis Data, Strong Cash Position, and Multi-Billion-Dollar Upside Potential

TD Cowen analyst Tyler Van Buren has maintained their bullish stance on ORKA stock, giving a Buy rating...

3M ago

ORKA

Oruka Therapeutics reports Q1 EPS (48c), consensus (54c)

“This was an important period for our company as we saw interim data for ORKA-001 that hit the...

3M ago

ORKA

Halozyme licenses Hypercon technology to Oruka Therapeutics in psoriasis

Halozyme (HALO) and Oruka Therapeutics (ORKA) announced that Halozyme’s wholly-owned subsidiary, Halozyme Hypercon, has entered into a global...

3M ago

HALO

ORKA

Oruka Therapeutics Completes Public Equity Offering Under Shelf

An update from Oruka Therapeutics ( ($ORKA) ) is now available. On April 28, 2026, Oruka Therapeutics entered...

3M ago

ORKA

Oruka Therapeutics price target raised to $120 from $109 at Leerink

Leerink raised the firm’s price target on Oruka Therapeutics (ORKA) to $120 from $109 and keeps an Outperform...

3M ago

ORKA

ORKA FAQ

What was Oruka Therapeutics, Inc.’s price range in the past 12 months?

Oruka Therapeutics, Inc. lowest stock price was $12.84 and its highest was $97.78 in the past 12 months.

What is Oruka Therapeutics, Inc.’s market cap?

Oruka Therapeutics, Inc.’s market cap is $5.56B.

When is Oruka Therapeutics, Inc.’s upcoming earnings report date?

Oruka Therapeutics, Inc.’s upcoming earnings report date is Aug 17, 2026 which is in 20 days.

How were Oruka Therapeutics, Inc.’s earnings last quarter?

Oruka Therapeutics, Inc. released its earnings results on May 13, 2026. The company reported -$0.48 earnings per share for the quarter, beating the consensus estimate of -$0.547 by $0.067.

Is Oruka Therapeutics, Inc. overvalued?

According to Wall Street analysts Oruka Therapeutics, Inc.’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Oruka Therapeutics, Inc. pay dividends?

Oruka Therapeutics, Inc. pays a Notavailable dividend of $19.356 which represents an annual dividend yield of N/A. See more information on Oruka Therapeutics, Inc. dividends here

What is Oruka Therapeutics, Inc.’s EPS estimate?

Oruka Therapeutics, Inc.’s EPS estimate is -0.51.

How many shares outstanding does Oruka Therapeutics, Inc. have?

Oruka Therapeutics, Inc. has 60,312,100 shares outstanding.

What happened to Oruka Therapeutics, Inc.’s price movement after its last earnings report?

Oruka Therapeutics, Inc. reported an EPS of -$0.48 in its last earnings report, beating expectations of -$0.547. Following the earnings report the stock price went up 1.14%.

Which hedge fund is a major shareholder of Oruka Therapeutics, Inc.?

Currently, no hedge funds are holding shares in ORKA

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Oruka Therapeutics Stock Smart Score

Neutral

Fundamentals

Return on Equity

―

Trailing 12-Months

Asset Growth

33.77%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Oruka Therapeutics, Inc.

Oruka Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel monoclonal antibody therapeutics for psoriasis (PsO), and other inflammatory and immunology (I&I) indications. Its lead products include ORKA-001 that targets p19 subunit of interleukin-23, which is in phase 2a trial for the treatment of PsO; and ORKA-002 that targets interleukin-17A and interleukin-17F, which is in phase 2 trial for the treatment of PsO, psoriatic arthritis, and other conditions. The company also develops ORKA-003 for targeting an undisclosed pathway; and ORKA-021, a sequential combination regimen of ORKA-002 and ORKA-001. Oruka Therapeutics, Inc. is headquartered in Menlo Park, California.

Oruka Therapeutics (ORKA) Earnings & Revenues

Historic Earnings Reports

ORKA Stock 12 Month Forecast

Average Price Target

$147.63

▲(60.18% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"10":"$10","181":"$181","52.75":"$52.8","95.5":"$95.5","138.25":"$138.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":180,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$180.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":147.625,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$147.63</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":120,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$120.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[10,52.75,95.5,138.25,181],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2025","6":"Jan<br/>2026","9":"Apr<br/>2026","12":"Jul<br/>2026","25":"Jul<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,93.29,99.96000000000001,106.63000000000001,113.30000000000001,119.97,126.64000000000001,133.31,139.98000000000002,146.65,153.32,159.99,166.66000000000003,173.32999999999998,{"y":180,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,93.29,97.4696153846154,101.64923076923077,105.82884615384616,110.00846153846155,114.18807692307692,118.36769230769231,122.5473076923077,126.72692307692307,130.90653846153845,135.08615384615385,139.26576923076922,143.44538461538463,{"y":147.625,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,93.29,95.3446153846154,97.39923076923077,99.45384615384616,101.50846153846155,103.56307692307692,105.61769230769231,107.6723076923077,109.72692307692307,111.78153846153846,113.83615384615385,115.89076923076922,117.94538461538461,{"y":120,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":11.8,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.6,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.56,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.62,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":28.17,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":27.67,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":30.31,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":34.3,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":33.69,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":50.43,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 42, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":62.58,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 60, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":55.01,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 102, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":93.29,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 90, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >